Nanoliposomal vinorelbine - Merrimack Pharmaceuticals

Drug Profile

Nanoliposomal vinorelbine - Merrimack Pharmaceuticals

Alternative Names: NanoVNB; Vinorelbine encapsulated liposome - Taiwan Liposome Company

Latest Information Update: 29 Nov 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator HERMES BioSciences
  • Developer Taiwan Liposome Company
  • Class Antineoplastics; Small molecules; Vinca alkaloids
  • Mechanism of Action Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer

Most Recent Events

  • 30 Sep 2013 Biomarkers information updated
  • 29 Nov 2010 Discontinued - Phase-II for Colorectal cancer in Taiwan (IV)
  • 09 Oct 2007 Nanoliposomal vinorelbine is available for licensing in the US, Europe and Japan (http://www.hermesbio.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top